Expected values for gastrointestinal and pancreatic hormone concentrations in healthy volunteers in the fasting and postprandial state.
Adolescent
Adult
Aged
Blood Glucose
Fasting
Female
Gastric Inhibitory Polypeptide
/ blood
Gastrointestinal Hormones
/ blood
Glucagon
/ blood
Glucagon-Like Peptide 1
/ blood
Glucose Tolerance Test
Healthy Volunteers
Humans
Insulin
/ blood
Male
Middle Aged
Obesity
/ blood
Pancreatic Hormones
/ blood
Peptide YY
/ blood
Postprandial Period
Reference Values
Young Adult
Glucagon-like peptide 1 (GLP-1)
analytical chemistry
glucose-dependent insulinotropic polypeptide (GIP)
immunoassay
peptide YY (PYY)
Journal
Annals of clinical biochemistry
ISSN: 1758-1001
Titre abrégé: Ann Clin Biochem
Pays: England
ID NLM: 0324055
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
pubmed:
12
11
2020
medline:
7
7
2021
entrez:
11
11
2020
Statut:
ppublish
Résumé
Gastrointestinal hormones regulate intestinal transit, control digestion, influence appetite and promote satiety. Altered production or action of gut hormones, including glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and peptide YY (PYY), may contribute to the biological basis of obesity and altered glucose homeostasis. However, challenges in analytical methodology and lack of clarity on expected values for healthy individuals have limited progress in this field. The aim of this study was to describe expected concentrations of gastrointestinal and pancreatic hormones in healthy volunteers following a standardized meal test (SMT) or 75 g oral glucose tolerance test (OGTT). A total of 28 healthy volunteers (12 men, 16 women; mean age 31.3 years; mean body mass index 24.9 kg/m Ranges of expected values were created for glucose, insulin, glucagon, GLP-1, GIP, PYY and free fatty acids in response to a standardized mixed liquid meal or OGTT. Intact proinsulin and C-peptide levels were also measured following the OGTT. These ranges of expected values can now be used to compare gut hormone concentrations between healthy individuals and patient groups.
Sections du résumé
BACKGROUND
Gastrointestinal hormones regulate intestinal transit, control digestion, influence appetite and promote satiety. Altered production or action of gut hormones, including glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and peptide YY (PYY), may contribute to the biological basis of obesity and altered glucose homeostasis. However, challenges in analytical methodology and lack of clarity on expected values for healthy individuals have limited progress in this field. The aim of this study was to describe expected concentrations of gastrointestinal and pancreatic hormones in healthy volunteers following a standardized meal test (SMT) or 75 g oral glucose tolerance test (OGTT).
METHODS
A total of 28 healthy volunteers (12 men, 16 women; mean age 31.3 years; mean body mass index 24.9 kg/m
RESULTS
Ranges of expected values were created for glucose, insulin, glucagon, GLP-1, GIP, PYY and free fatty acids in response to a standardized mixed liquid meal or OGTT. Intact proinsulin and C-peptide levels were also measured following the OGTT.
CONCLUSIONS
These ranges of expected values can now be used to compare gut hormone concentrations between healthy individuals and patient groups.
Identifiants
pubmed: 33175577
doi: 10.1177/0004563220975658
pmc: PMC7961662
doi:
Substances chimiques
Blood Glucose
0
Gastrointestinal Hormones
0
Insulin
0
Pancreatic Hormones
0
Peptide YY
106388-42-5
Gastric Inhibitory Polypeptide
59392-49-3
Glucagon-Like Peptide 1
89750-14-1
Glucagon
9007-92-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108-116Subventions
Organisme : Wellcome Trust
ID : WT084210Z/07/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00014/5
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT088357Z/09/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12012/5
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12012/3
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00014/3
Pays : United Kingdom
Références
J Diabetes Complications. 2015 Apr;29(3):445-50
pubmed: 25623632
Obes Surg. 2012 Jul;22(7):1084-96
pubmed: 22359255
Eur J Endocrinol. 2014 Mar 08;170(4):529-38
pubmed: 24412928
Surg Obes Relat Dis. 2007 Nov-Dec;3(6):597-601
pubmed: 17936091
Cell Metab. 2006 Sep;4(3):223-33
pubmed: 16950139
Obesity (Silver Spring). 2015 Jul;23(7):1362-70
pubmed: 26054049
Clin Endocrinol (Oxf). 2005 Jan;62(1):51-5
pubmed: 15638870
Physiol Rev. 2007 Oct;87(4):1409-39
pubmed: 17928588
Diabetes Obes Metab. 2014 Nov;16(11):1155-64
pubmed: 25041349
Diabetes. 2011 Dec;60(12):3103-9
pubmed: 21984584
Am J Clin Nutr. 2015 Sep;102(3):540-7
pubmed: 26201818
J Clin Endocrinol Metab. 2010 Jan;95(1):333-7
pubmed: 19875483
Ann Surg. 2006 Jan;243(1):108-14
pubmed: 16371744
Diabetes. 2015 Jul;64(7):2513-25
pubmed: 25677912
J Clin Endocrinol Metab. 2015 Feb;100(2):561-8
pubmed: 25375983
Int J Obes Relat Metab Disord. 1999 Mar;23(3):304-11
pubmed: 10193877
Diabetes Care. 2007 Jul;30(7):1709-16
pubmed: 17416796
Metabolism. 2014 Feb;63(2):226-32
pubmed: 24290838
Diabetes. 2019 May;68(5):1062-1072
pubmed: 30733330
Lancet. 1987 Dec 5;2(8571):1300-4
pubmed: 2890903
J Clin Endocrinol Metab. 2019 Dec 1;104(12):6403-6416
pubmed: 31276156
Hum Nutr Clin Nutr. 1985;39 Suppl 1:5-41
pubmed: 4044297
J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13
pubmed: 12788877
Gastroenterology. 2006 Jan;130(1):44-54
pubmed: 16401467
Clin Chem. 1998 Mar;44(3):622-31
pubmed: 9510871
Diabetes. 2001 Mar;50(3):609-13
pubmed: 11246881
Surg Obes Relat Dis. 2018 May;14(5):562-568
pubmed: 29548882
Diabetes. 2016 Mar;65(3):585-97
pubmed: 26672094
Diabetes. 2016 Nov;65(11):3473-3481
pubmed: 27504013